An official journal of the Society for Neuro-Oncology. Publishes high-quality research and information in all areas of neuro-oncology.

Curis, Inc.

January 18, 2018 - Get the latest biopharma news, clinical trial updates, and industry insights at PipelineReview.com. Discover innovative therapies and regulatory news.

Taiclone is the Best supplier in Antibodies, Proteins & Peptides, ELISA Kits and Biochemicals. Now shipping world wide!

Online ISSN: 2051-1426 Copyright © 2023 BMJ Publishing Group Ltd & Society for Immunotherapy of Cancer. All rights reserved

Explore new Orange County, CA research studies at UC Irvine. We have trials for adults, children, seniors, and healthy volunteers.

March 16, 2021 - An official website of the United States government · Here’s how you know

October 14, 2020 - Browse · Discover research from American Chemical Society · RSS feed · Follow · ALLCategoriesJournalsSEARCH · Hide footer · figshare. credit for all your research

Siteman Cancer Center provides all the services surrounding cancer diagnosis and treatment that patients and their families might need.

Find products, read reviews and hear about the latest technological developments on Biocompare

Access 160+ million publication pages and connect with 25+ million researchers. Join for free and gain visibility by uploading your research.

Bovine Serum Albumin | D-Luciferin Sodium Salt | D-Luciferin Potassium Salt | DTT | HEPES Free Acid | IPTG | Proteinase K | TCEP HCl | X-Gal

Bapat, V., Weiss, E., Bajwa, T., Thourani, V. H., Yadav, P., Thaden, J. J., Lim, D. S., Reardon, M., Pinney, S., Adams, D. H., Yakubov, S. J., Modine, T., Redwood, S. R., Walton, A., Spargias, K., Zhang, A., Mack, M. & Leon, M. B., Jun 24 2024, In: JACC: Cardiovascular Interventions.

August 1, 2024 - CTV is a better way to find clinical trials. Find trials for common conditions, or customize your search with location, treatment, and status filters.

Antibodies, Proteins and ELISA kits | Life Science reagents

January 27, 2022 - CA-4948 works by interfering with the signaling pathways involving IRAK4, and its efficacy is still being explored. The data presented is preliminary, however, the Phase I study (NCT042787688) aims to determine the safety profile and tolerance of this novel agent in enrolled patients.